Open Nav

RadioMedix Inc

  • Izabela Tworowska, RadioMedix Inc

looking for the business partners interested in development of radiolabeled drugs

  • Date:Thursday, October 18
  • Time:2:15 PM - 2:30 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:RadioMedix, Inc. is a clinical stage biotechnology company based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company was founded in 2006 with a primary focus on the commercializing of radiotherapeutics and diagnostics agents for the orphan diseases. RadioMedix has two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical trials and Molecular Imaging Facility for in vitro/in vivo evaluation of agents. Our company has served as a sponsor and collaborator of Phase I/II and Phase III NDA enabling clinical trials. RadioMedix is an US-exclusive distributor of ITG GmbH (Germany) products and Trasis SA (Belgium) automated synthesizers for radiolabeling. RadioMedix serves also as a contract research project organization for partners interested in the development of radiolabeled probes.
  • Company Website:www.radiomedix.com
  • Company HQ City:Houston
  • Company HQ Country:United States
  • Company HQ State:Texas                            
  • CEO/Top Company Official:Ebrahim S. Delpassand, MD
  • Year Founded:2006
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :AlphaMedix-agent tagged with an alpha-emitter with affinity to neuroendocrine tumors.
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Previous and Current Investors:Private
  • Size of Last Investment Round:$2M ( private investors)
  • Total Amount Raised to Date, In All Rounds:$ 5.2M ( grants, contracts, TETF)
Speakers
Izabela Tworowska
RadioMedix Inc
Back